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Available online 7 March 2017A fast track “Hot Start” process was implemented to launch the European Bank for Induced Pluripotent Stem Cells
(EBiSC) to provide early release of a range of established control and disease linked human induced pluripotent
stem cell (hiPSC) lines. Established practice amongst consortium members was surveyed to arrive at harmonised
and publically accessible Standard Operations Procedures (SOPs) for tissue procurement, bio-sample tracking,
iPSC expansion, cryopreservation, qualification anddistribution to the research community. Thesewere implement-
ed to create a quality managed foundational collection of lines and associated data made available for distribution.
Here we report on the successful outcome of this experience and work flow for banking and facilitating access to
an otherwise disparate European resource, with lessons to benefit the international research community.
eTOC: The report focuses on the EBiSC experience of rapidly establishing an operational capacity to procure, bank
and distribute a foundational collection of established hiPSC lines. It validates the feasibility and defines the chal-
lenges of harnessing and integrating the capability and productivity of centres across Europe using commonly avail-
able resources currently in the field.© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Since their introduction in 2007 (Takahashi et al., 2007) hiPSC have
been rapidly and broadly incorporated into research to understand their
potential for disease. This has substantiated interest to incorporate this
resource into drug discovery pipelines, prospective patient stratifica-
tion, recruitment for clinical trials and post-clinical drug assessment of
safety issues following rare event reporting. However, the evolution of
these applications depends on facilitated and unfettered access to a
standardised and well characterised hiPSC resource to help avoid dis-
semination of unauthenticated or substandard cell lines to the research
community. Rising demand by academia and industry has instigated a
number of large scale public and privately funded disease and/or popu-
lation oriented hiPSC banking initiatives in the US, Japan and UK
(McKernan andWatt, 2013). Thesewill foreseeably improve the consis-
tency with which new cell lines will be developed but not necessarily
the standardised and scalable distribution of pre-established or new
lines to the wider hiPSC research community.
At present in Europe, a human pluripotent stem cell registry (www.
hPSCreg) offers the research community, legislators, regulators and the
general public ameasured overview of the current status of human plu-
ripotent stem cell research though the provision of information on
established cell lines derived from embryos or induced from adult cell
sources. At time of writing over 452 hiPSC lines are on the registry,
sponsored by EU, nation specific and charitable funding sources. How-
ever, this resource does not facilitate standardise access to these re-
sources which still require user interface with institutional
representatives in possession of any given cell line. Recognising a need
for a harmonised framework of best practice, the Innovative Medicines
Initiative Joint Undertaking (IMI JU), a pan-European public private
partnership between the European Commission (EC) and European
Federation of Pharmaceutical Industries and Associations (EFPIA;
www.efpia.eu), issued a call for proposals which in January 2014 culmi-
nated in the launch of the European Induced Pluripotent Stem Cell Bank
(EBiSC). EBiSC's mission has been to: i) identify key cohorts of patients
useful for research purposes within the wider scientific community, ii)
create a large single European hiPSC repository through the integration
of existing infrastructure, such as for example hPSCreg, and iii) generate
a centre of scientific excellence for standardisation and optimisation of
cryopreservation, retrieval and differentiation methods for hiPSC lines.
Here we report on the experience of the first stage of this initiative, a
fast track “Hot Start” process whose goal was to rapidly establish opera-
tional capacity and a distributable foundational collection of established
hiPSC lines.
2. Results
The Hot Start experience and outcomes were embodied in
established and conceived infrastructure provided by its membership.This was both as originally proposed and subsequently informed and
amended in the course of operational experience as follows.
2.1. Infrastructure set up
2.1.1. EBiSC Consortium membership and organisation
The founding EBiSC membership consisted of 6 EFPIA partners
defining industrial demand for a standardised hiPSC resource, and 23
non-EFPIA partners. The latter consisted of 6 Small Medium-sized
Enterprises (SME), 15 academic/research institutions and two
governmental agencies (Supplementary Fig. 1). Contribution of
members was organised in a 7 work-package (wp) programme
addressing management (wp1; governance, policy, hiPSC market
assessment, communication and dissemination), creation of the bank
(wp2; procurement, operation and sustainability), process improve-
ment (wp3; cryopreservation and automation), public engagement
(wp4; ethics, training), quality control and characterisation (wp5),
end use (wp6; storage, distribution and product validation), and data
management (wp7; information management system development
and long-term operation). At the outset of the programme a consortium
participant agreement stipulated that the hiPSC lines deposited in EBiSC
could be used for research by both for profit and not for profit organisa-
tions and the ongoing rights of access of all participants to the new
knowledge created as part of the Hot Start process.
2.1.2. Workflow design and outputs
The focus of the Hot Start process was to establish a workflow be-
tween hiPSC supplying centres, a Central Bank or Facility for quality
control, and ancillary sites responsible for storage, management and
distribution of information and cells to users (Fig. 1). This effort culmi-
nated in the establishment of the Hot Start collection comprised of
established hiPSC lines and related data and clinical links provided by
7 research organisations across 5 Europeanmember states (UK, Germany,
Denmark, Netherlands, and Spain). It also resulted in the establishment of
a bespoke information management system (IMS) supporting the stor-
age, organisation and presentation of EBiSC data to accommodate diverse
user interests: Cell line depositors, communicating resource details; EBiSC
staff using the IMS to track internal operations; bioinformaticians
requiring programmatic access to well-structured data; and prospective
cell line users procuring lines in accordance with selection criteria such
as donor disease representation and methodology used to create the
resource.
2.1.3. Definition of minimum essential information
Thede facto variability across supplying centres in the provenance of
hiPSC lines (i.e. terms of consent, information available on donors and
lines and methods applied to generate the lines), required definition
of minimum essential attributes to accept established lines for deposi-
tion in the bank and consensus operational standards and procedures.
Fig. 1. EBiSC Hot Start harmonised banking of established hiPSC lines. A: Consensus standardised protocols were implemented to collect and upload pre-existing donor and cell line
information to HPSCreg and expand, cryopreserve and ship hiPSC lines to Central Bank. B: At the Central Facility cell lines were registered and evaluated as part of the standardised
quality control procedure. C: Approved hiPSC line batches were shipped for final storage and worldwide distribution by e-commerce.
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included:
i) That the donation was voluntary, without financial or other ben-
efit;
ii) Donor de-identification and traceability;
iii) Definition of scope and/or restrictions on permitted use of donat-
ed material;
iv) Potential for access via providing centre to genetic and clinical in-
formation made available with the primary cell donation;
v) No expectation of feedback regarding incidental findings, data or
information arising from research use of cell lines.
Given that several iPSC lines identified of interest for initial usewere
originally not consented explicitly or had unclear conditions of
consenting for use by for profit organisations, the decision was made
to not use this as an exclusion criterion, as necessary reconsenting do-
nors. How readily hiPSC supplying centres provided minimal essential
information varied in accordancewith the strength of pre-existing rela-
tionships with clinical centres providing access to donors.
2.1.4. Standardisation of methods and labelling
Standard documents drafted and implemented as part of the estab-
lishment of the Hot Start collection included: i) forms and protocols for
the collection of historical information on donor and cell line history;
and ii) procedures for hiPSC culturing and banking. The former included
the essential requirement to define clear cell line ownership for subse-
quent use of an EBiSC standardisedMaterial Deposition and User Access
Agreements. An EBiSC template for Patient Information and Consent
(PIC), was useful in the event the terms of the original PIC used by thederivation centre failed to comply with minimum essential require-
ments and it was possible to re-consent the donor. Standard culture
and banking procedures included protocols for feeder-free hiPSC
growth, cryopreservation and storage, batch specific labelling, testing,
release and shipment at the hiPSC supplying research centres, Central
and Mirror Banks and distribution centres (See Experimental Proce-
dures and Supplementary Figs. 2,3).
Labels were provided by the Central Bank and founded on the prin-
ciples of hiPSC line identification previously established by the European
hPSCreg registry (www.hPSCreg.eu; Seltmann et al., 2016). Label design
and nomenclature evolved over 24 months from prototypes to enable
the incorporation of operational feedback and requirements (Fig. 2).
Changes encompassed inclusion/omission of depositor derived identi-
fiers, machine readable identifiers compatible with existing operational
systems (eg. Askion automated cryopreservation, Neubauer et al., 2015;
European Collection of Authenticated Cell Cultures), unique biosample
accession numbers (Gostev et al., 2012), EBiSC logo and batch and vial
numbers. Partner performance of consensus protocols was reinforced by
semi-annual practical and theoretical training courses. Feedback from
the first two training courses confirmedmajority satisfaction with course
effectiveness and utility (Supplementary Fig. 4).
2.1.5. Data management
Pre-existing or hiPSC supplying centre generated Information avail-
able for each hiPSC line were uploaded onto hPSCreg. Three categories
of information were collated:
i) Background information on the donor and methods used to cre-
ate the cell line, including donor age, gender, origin, and disease
association, genetic lesion/clinical diagnosis, identity of primary
Fig. 2. Standardisednomenclature and labelling. Labelling content and format adhered to principles of hPSC registration established by hPSCreg, and requirements of operator andmachine
readable identifiers, at the Central andMirror Banks and distribution centre (Public Health England, ECCAC). This evolved in the course of the first 24months of the EBiSCHot Start (A–D).
Changes included switch from a 1 to 2 dimensional machine readable identifier and incorporation of EBiSC branding (A to B), and inclusion and then omission of supplying centre
identifying information (B to D). EBiSC nomenclature (E) identifies depositing supplier (BION, reference to Bioneer A/S), identity as an iPSC line and donor, clone and sub-clone
numbers, augmented further by batch, vial and ECCAC catalogue numbers noted separately. Each vial was also given a unique biosamples accession numbers (Gostev et al., 2012; in
this example SAMEA4303179).
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ology (genes, vectors, cell culture history);
ii) historical data on hiPSC characterisation, including sterility, viral
pathogen screening, pluripotency potential, confirmation of ge-
netic lesion (if known) (Exemplar, Supplementary Fig. 5); and,
iii) quality control data collected in the course of cell expansion and
banking for theHot Start process including viability, morphology,
mycoplasma, genetic identity (DNA microsatellite PCR) and in-
tegrity (karyology) and cell phenotype (minimum expression
of 3 pluripotency associated biomarkers).
For each hiPSC line, data was collated to prepare a Certificate of
Analysis (CoA)whose accuracywas independently checked by a Quality
Assurance team before subsequent distribution of cell lines to the
Mirror Bank with a fully automated extended cryopreservation cold
chain (Fraunhofer IBMT, http://www.ibmt.fraunhofer.de/en.html), and
the distribution centre (ECACC), (Supplementary Fig. 6a,b). As lines
were received at the distribution centre they were registered on an
Oracle based inventory and stock control system with links into the
e-commerce website (https://cells.ebisc.org). On the latter, each
hiPSC line is set up with a basic data set providing key information
along with downloadable associated documents such as Material
Safety Data, technical handling information, Access Use Agreement
(AUA), and end user hiPSC culture protocols. The site also provides
the facility to download CoA upon entry of the batch number of the
cells received by the end user. Upon distribution centre receipt of a
signed AUA, hiPSC lines are despatched to end users within ECACC's
standard practice of 5 business days worldwide. To date this has
included centres in the UK, Germany, Denmark and the USA.2.2. Operational experience
2.2.1. hIPSC line supply
Of the 7 supplying centres, 4 centres fulfilled or were on course to
fulfil all aspects of their commitment to provide established lines as of
March 2016. One supplier encountered late-stage reluctance of clinical
partners fromwhich cells were donated to accept terms of material de-
position and transfer agreements which potentially would make the
lines immediately available to the research community prior to deposi-
tors' publication of research on the lines being deposited. Two suppliers
were unable to locate viable cell line stocks with no viable alternatives
available. With the exception of a supplier based in Spain, all centres
were able to agree to deposit the lines in a Central Bank and subsequent
centralised distribution. The law of Spain requires project specific ap-
proval by a national authority and Spanish administrative control over
distribution of hiPSC lines to other partners in the EBiSC consortium or
third parties. For proof of concept validation of consensus protocols
and quality control measures, project specific approval was secured
for shipment of the Spanish hiPSC lines to the Central Facility and use
therein, demonstrating that even across national sovereign legislation,
EBiSC was able to operate to facilitate international cell line transfer.
Initially 7 hiPSC supplying research centres were asked to commit to
providing 8–10 hiPSC lines established by them. This yield a final total
commitment of 47 hiPSC lines representative of diverse donor health
and disease status and clonal variation. Progress against key perfor-
mance milestones at months 17 and 29 is summarised in Fig. 3. The
first hiPSC lines were received by the Central Bank 8 months after the
launch of the programme, and distributed directly to a third party user
by 12 months. However, it took 17 months until a majority of the cen-
tres (4) had deposited both the cell line batches and the required data
Fig. 3. Key Performance indicators (KPI) of Hot Start hiPSC supplying centres. After identification of 8–10 suitable cell lines, centres were required to undergo a number of processes to
enable cell line release. After performing expansion and banking, each cell line was distributed to the Central Facility for additional QC, data review and formal release to ECACC.
Progress in these KPIs over the project period after Month 17 and 29 (May 2015 & 2016) are shown here as cell line distribution to the Central Bank (A), completion of Material
Deposition Agreement (B), distribution to Central Facility (C), anonymised donor data deposition (D), cell line batch data deposition (E) and cell line batch release data to distribution
centre (F). E-commerce distribution of a specific cell line from the distribution centre required all of these parameters to be fulfilled. All parameters are assessed relative to the number
of prospective lines initially identified, increases above 100% are due to depositors being required to repeat cell line batch production and characterisation subsequent to a failure of
the first batch.
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project month 29) another two reached these endpoints for a fraction
of their lines.
Lines released for public distribution represent cell line batches
whereby all requirements had been satisfied; consent information had
been approved, an MDA had been completed, and the Central Facility
has received a batch, and approved characterisation data and the line
had passed Quality control at the Central Facility. By the time of the for-
mal launch of the EBiSC catalogue 27 months into the programme on
23rd of March 2016 (https://cells.ebisc.org), 27 of the 47 lines (57%)
provided by 5 of the depositors were available by e-commerce. To vali-
date the pluripotent phenotype of ECACC distributed lines a selected
line (UKBi005-A, depositor and EBiSC QC data for which is provided in
Supplementary Fig. 5 for)wasprocured from the distributing centre, ex-
panded and submitted to a high content imaging analysis focussing on
the pluripotency characteristics of the material provided. Immunofluo-
rescent staining and quantification of pluripotency markers OCT3/4/
POU5F1, SOX2, NANOG and LIN28 revealed high amounts of positive
cells under consensus culture conditions (91% OCT3/4/POU5F1, 81%
SOX2, 73% NANOG and 78% LIN28) (Supplementary Fig. 7).2.2.2. Central Banking
Retrospective assessment of the experience of the Central Bankwith
supplied lines is summarised in Fig. 4. Of the 47 Hot Start cell line
batches deposited (Supplementary Figs. 8–10), 9 failedQC at the Central
Bank, 6 of whichwere able to be recovered from cell stocks and replace-
ment batches produced either by the Central Bank or by depositors di-
rectly. Approximately 87% of cell lines recovered well post-thaw,
growing to confluence within a suitable timeframe and exhibiting ac-
ceptable or very acceptable morphology with low to medium levels of
spontaneous differentiation, typical of that of human pluripotent stem
cells. Cultivation of the poorly recovered lines necessitated common op-
erator practises of low split ratios at passage andmechanical removal of
differentiating cells to adapt lines to implemented protocols and their
expansion for quality control at the Central Facility. By the time of cryo-
preservation all expanded lines were viable and showed acceptable
phenotype and pluripotent potential, allowing release and distribution.
All EBiSC banked lines were tested for sterility, mycoplasma and
contamination with human viral pathogens (HIV-1 and -2, Hepatitis B
& C), the latter by PCR nucleic acid testing. Three of the lines (6%) had
to be discarded due to microbial contamination and all but one line
Fig. 4.Quality Control at Central Bank. Release of cell lines for sale and distributionwas dependent on passing core release, quality control screening performed at the Central Bankwhose
outcomes for each parameter is assessed in relation to the total number of lines committed by supplying centres (n= 47).
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positive for HIV-1 but further investigation discovered a cell line identi-
ty error and the depositor was unable to identify the correct source ma-
terial, the most frequent of QC fails identified. Using PCR to assess DNA
microsatellite markers, the identity of 17% of deposited cell lines dif-
fered from that intended. Potential root causes for these were not fully
confirmed but were likely to include switching of cell lines at cryopres-
ervation, concurrent cell processing of different lines or mislabelling
during reprogramming and processing.
2.3. The Hot Start Collection
Based on information registered on hPSCreg for the 27Hot Start lines
available for distribution at the time of the Catalogue launch, we com-
pared the collection against the total population of hiPSC lines on the
registry for which information has been validated. At time of launch
this amounted to 283 hiPSC lines from 17 iPSC supplying centres, ex-
cluding the available 27 Hot Start lines. Results are depicted as a ring
graph in Fig. 5, with corresponding numerical and percentage values
tabulated in Supplementary Fig. 11 A, B). Diseases represented by avail-
able lineswere broadly classifiable asNeurological Disorders (37%), Car-
diac Disease (19%), and Eye Disease (15%). Approximately 30% of the
Hot Start lines were sourced from disease unaffected donors, as com-
pared with 72% on the registry. For both the collection and lines on
the registry, the majority (78–85%) originated from fibroblast cells.
Blood erythroblasts were also included in both. Over two thirds (74%)
of theHot Start collection were created using a range of non-integrating
vectors, namely RNA (Sendai, 37%), episomal plasmid DNA (26%) or ex-
cisable transposon (11%) vectors. A comparable proportion of hiPSC
lines on hPSCreg were created using non-integrating methods,predominantly Sendai virus (70%). The overwhelming majority of all
lines in the Hot Start collection (81%) and hPSC registry (86%) were
reprogrammed using the original Oct4 (POU5F1), Sox2, KLF4, c-Myc
combination as originally reported by Takahashi et al., (2007). As
regards culture systems used originally to derive the lines, 74% and
26% of the Hot Start lines were derived in mTESR and E8, respectively
as compared with 4% and 3% for lines on the registry. The predominant
matrices were Vitronectin (53%, registry) and Matrigel/Geltrex (74%,
Hot Start). In both cases the predominant method of cell passaging
was EDTA (100% versus 56%, Hot Start vs registry). We intentionally
sought gender balance in the Hot Start collection based on availability
at time of banking (52% vs 48% m:f).
3. Discussion
The EBiSC Hot Start yielded a distributable resource of 27 pre-
existing hiPSC lines constituting lines for which depositors had the
greatest available data and working experience. As compared with EU
registered lines, hiPSC in the Hot Start Collection also predominantly
originated by reprogramming of fibroblasts by the canonical OKSM
combination of transcription factors. However, the proportion of lines
reflecting use of more modern technology and methods for hiPSC line
derivation was greater in the collection than for lines on the registry
across the spectrum of other modifiable parameters (i.e. media, matri-
ces, passaging method, reprogramming vectors).
Key lessons arising from the Hot Start experience included the
following:
1. Depositor priorities. Although facilitating third party user access to
hiPSC lines is central to the EBiSC mission the first bottleneck to
Fig. 5. EBiSC Hot Start collection representativeness in relation to hiPSC validated in hPSCreg. A) Disease association of hiPSC donors from the Hot Start collection (blue) compared to
publically viewable hiPSC lines in the hPSCreg database; Additional cell line characteristics compare hPSCreg data (outer circle) versus the Hot Start collection (HS, inner circle): B)
primary material for reprogramming; C) reprogramming method; D) transgenes used in reprogramming; E) culture medium; F) culture matrix; G) passaging.
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able to the wider research community and competitors prior to pub-
lication or commercial development may slow the pace with which
the benefits offered by banking initiatives are realised.
2. Data and stock storage. Delays due to issues obtaining and collating
historical cell line data were common and retarded progress. Addi-
tionally, multiple issues were observed around poor prior labelling
of cryopreserved cell line stocks, leading to both cell line identity fail-
ures and irreplaceable loss of cell batches, underscoring the impor-
tance of cell line identity checking bymicrosatellite DNA assessment.
3. Legal governance. The lengthy negotiations involved in the initial for-
mulation of EBiSC template agreements pertaining to materialdeposition and distribution, and the institution-specific adaptations
required to facilitate their implementation, ultimately impeded the
rate at which cell lines were deposited andmade available for distri-
bution. The obstacle presented by Spanish law, which precludes the
distribution of Spanish donor derived pluripotent stem cells (hiPSC
and hESC) by an entity other than a Spanish authority, required test-
ing and the boundaries set by the EBiSC project provided the perfect
setting for engagement to explore what future adjustments to legal
constitution might be feasible. Other legal or cultural norms, such
as a protective patient-clinician relationship, data protection laws,
or requirement of absolute donor anonymity may be found to im-
pose further restrictions on efforts to globalise procurement.
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tre wide diversity of hiPSC line provenance (i.e. cell of origin,
reprogramming, culture and cryopreservation methods) the pro-
gramme was successful in implementing standardised feeder-free
culture conditions (Ludwig et al., 2006; Chen et al., 2011) using com-
mercially sourced reagents. The provision of several training courses
was perceived as critical for this. The robustness of these feeder-free
protocols was further substantiated by a pilot study undertaken in
collaboration with another IMI funded initiative, StemBANCC
(www.stembancc.org) focused on provision and use of well
characterised patient derived hiPSC for use in drug discovery, where-
in lines banked under feeder-dependent cultures were transitioned
directly and banked under feeder-free conditions (data not shown).
5. Value of batch testing for sterility and identity. The importance of mea-
sures to safeguard against microbiological contamination and
mislabelling of cell lines is broadly understood and avoidable
through implementation of high quality standards of operation
(Stacey et al., 2013). The danger of procuring lines from sources
other than banks routinely implementing these measures as a
batch release criterion is underscored by our experience. The inci-
dence of mycoplasma contamination is estimated to be around 5–
30% of cell lines across theworld (Nikfarjam and Farzaneh, 2012). Al-
though the number of cell lines screened was modest (i.e. 47) and
centres sampled was small (n= 7), mycoplasma were not detected
in any deposited hiPSC line as assessed by both direct colony growth
and a high sensitivity, indirect qPCR basedmethod. Checking for cul-
ture sterility by inoculating liquid microbiological growth media
with spent culture media and incubation for 14 days, rather than
less stringent visual assessment of cell cultures in process, revealed
only a low incidence (3/47) of bacterial contamination of undeter-
mined type. This was thought to arise from the occurrence of low
level bacterial contamination which was not observed, even in anti-
biotic-free cultures due to the daily media changes applied to cul-
tures but may also have been due to variability in contamination
levels in the laboratory of origin.
6. Labelling. Defining traceable nomenclature and labelling terms in-
volved substantial and iterative inter-institutional discourse. Initially,
the local cell line name was added as a safety measure to ensure the
correct labels were used during cryopreservation. The switch to 2D
barcodes was made to improve barcode scanning compatibility
with an established automated cryostorage system. Due to repetitive
cell line identity failures and/or incorrect clone IDs recorded prior to
deposit, the local cell line name was subsequently removed. Co-inci-
dentally the distributing centre (ECACC) catalogue number was
introduced.
7. Interface with established public resources managing information and
cell lines. Key to the future sustainability and quality of EBiSC re-
sources initiated by theHot Start process is the interface and integra-
tion of well established public resources for data and cell
management. For example, the hPSCreg project is independently
funded by the European Commission to provide a central resource
of hPSC lines along with ethical provenance, and it has emerged as
the established community standard for iPSC registration
(Seltmann et al., 2016). hPSCreg issues certificates to verify that a
registered line meets strict minimal data requirements, and this certif-
icate is nowrequiredby a cell line before it canbe included inproposals
for EC research funds. It also provides the portal for registration of lines
for banking and distribution by EBiSC. A fast track registration process
for EBiSC lines has been set up to enable rapid processing for accession
of EBiSC lines although certification of lineswill still require completion
of hPSCreg minimal requirements. A guide for registration has been
prepared to assist depositors (http://www.ebisc.org/files/Other-doc/
01-QuickStartGuideCellLineRegistration-2016-06-14-V2.pdf). EBiSC
automatically registers all of its hiPSC cell lines in the BioSamples da-
tabase at EMBL-EBI. This ensures that any hiPSC assay data, generat-
ed on EBiSC cell lines and deposited in the EMBL-EBI archives (suchas RNA-seq or array data) can be directly linked to the EBiSC cata-
logue enabling rapid user access to molecular data where it is avail-
able. EBiSC uses ontology tools hosted by EMBL-EBI to annotate cell
lines using a controlled vocabulary, which ensures cell line scientific
data are accurately described and more easily discoverable in the
web portal. EBiSC has arranged for cell line data to be shared, seam-
lessly and automatically, between the different components of the
IMS network ensuring that the data is up to date and content is val-
idated when released to the public. This includes hPSCreg, the IMS
database, ECACC, the central facility's Laboratory Information Man-
agement System (LIMS), and the Biosamples database. Depositors
and prospective users/customers benefit from the assurance that
cell line data is consistent across these services, for all cell lines. Last-
ly the IMS provides a user-friendly application layer for searching
across hiPSC lines and associated datasetswithin the EBiSC collection
and provides support to internal business operations and manage-
ment of cell line data.
8. Donor information. At present hiPSC donor information supplied and
publicly available through such capacity as provided by hPSCreg is
limited. There is broad recognition in the field of worries in gathering
andmaking detailed clinical information andmedical records public-
ly available in relation to privacy and consent associated issues
(Peppercorn et al., 2012; Bastião Silva et al., 2015). From a ‘database
point of view’ the presentation of clinical data as free text is not pre-
ferred as this complicates searching and comparing clinical informa-
tion between donors. Rather, standardised taxonomies and
ontologies should be developed and used to describe a disease and
there are ongoing efforts to this effect amongst pertinent institutions
within EBiSC (EBI). Existing standards such as Systematised Nomen-
clature of Medicine (snowmed), the International Classification of
Diseases (ISO), or disease ontologies should be applied if possible.
At the moment, hPSCreg registers clinical data related to diagnosed
disease(s) based on experimental factor ontology (EFO) (Malone et
al., 2010) and disease ontology (DO) (http://www.disease-
ontology.org) standard terms by applying a semantic mapping tool
Zooma (Sarntivijai et al., 2016), but also allows for free text informa-
tion. In addition, genetic disease carrier status, family history, dis-
ease- and non-disease related phenotypes can be provided as free
text. Furthermore, disease - and phenotype - associated mutations/
polymorphisms can be registered for each of the diagnosed diseases
of a donor, also using standard nomenclatures of theHumanGenome
Variation Society (HGVS). The already implemented standardised at-
tributes allow direct comparison and searching, without additional
free text analysis. HPSCreg also asks depositors whether medical his-
tory files or clinical information for the donor are available upon re-
quest. Compliance with providing clinical and genetic donor
information together with cell line information is a major bottleneck
and could behelped by incentive or assistance to depositors provided
by banking establishments such as EBiSC.
In summary, we describe here the feasibility and challenges of co-
ordinating existing organisational capacities across Europe to fast
track the establishment of a centralised network and facilities to access
a standardised resource of established hiPSC lines and data. The avail-
ability of these should benefit the accessibility, comparability, reproduc-
ibility and efficacy of ongoing research on this resource in all sectors,
public and private. Additionally, EBiSC experience and infrastructure
can benefit future efforts to standardise the procurement and deriva-
tion of new hiPSC lines. A prospective depositor's early engagement
with EBiSC could aid in the avoidance of costs of local banking and
quality control not to mention provides a safe off-site depository.
To this end, EFPIA member sponsored production of hiPSC lines,
whose costs are partly subsidised by EBISC, are ongoing for diseases
for which there is researcher demand not currently met by existing
supply.
Recently, guidelines prepared by the International Society for Stem
Cell Research (ISSCR) for global standards for stem cell research and
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(see Commentary, Daley et al., 2016). Review of these to confirm com-
plicity and alignment of hiPSC lines banked as part of EBiSC Hot Start
launch verified that for the guidelines which were applicable (eg. pro-
curement, processing and banking) EBiSC hiPSC lines either complied
or enable compliance by third party users (Supplementary Fig. 12).
Thismakes the EBiSCHot Start collection and ongoing advances in infra-
structure of broader global benefit to other small and large scale hiPSC
derivation and banking initiatives.
4. Experimental Procedures
4.1. hiPSC processing
Protocols used for feeder-free hiPSC culture, passaging and cryopres-
ervation (available on line: http://www.ebisc.org/files/Other-doc/
EBiSC-User_Protocol-V2-2015-06-11-V0.1.pdf) and consisted of two
methods consisting of mTESR and Matrigel/Geltrex or E8/Vitronectin
culture in 5% CO2 in air (37 °C), with EDTA based cell passaging
(Ludwig et al., 2006; International Stem Cell Initiative Consortium,
2010; Chen et al., 2011). At time of cell harvesting each batch of cells
were lifted from individual vessels and pooled prior to dispensing into
pre-labelled sequentially numbered vials. Lines were cryopreserved as
aliquots of 1–2 × 106 cells per vial as clumps of cells in either Cryostor
or DMSO based freeze mix of 10% DMSO in FBS and/or culture medium.
4.2. Identity testing
Identity testing was performed by 16 allele STR profiling
(PromegaPowerplex 16, performed by Source Biosciences).
4.3. Viability testing
Viability testing was performed by observation of culture recovery
over 48 h and assessment of cultures graded according to number and
appearance of typical hPSC colonymorphology. Thesewere subjectively
assessed as very acceptable, acceptable or unacceptable.
4.4. Mycoplasma testing
This was performed by RT PCR using appropriate limit of detection
controls (MycoSeq, Life Technologies). A standard 28 day culture
screening was also performed (ECACC and mycoplasma experience).
4.5. Sterility testing
Sterility testing was performed according to methods based on the
European Pharmacopeia standard. Specifically, 0.5 ml to 1ml of cell cul-
ture supernatant were aseptically inoculated into sterile Tryptone Soya
Broth (TSB), Fluid ThioglycollateMedium(FTM) and SabaroudDextrose
Broth (also known as Sabaroud Liquid Medium, SLM, where performed
at NIBSC) respectively and incubated at 37–39 °C (THB, FTM) or 20–
25 °C (SLM) for up to 14 days and observed periodically (on days 3, 4
or 5; 8, 9 or 10) and on day 14 for evidence of microbial growth.
4.6. Flow Cytometry
The proportion of the population expressing stem cell markers,
SSEA-4, SSEA-1 and TRA-1-60, was assessed (BD Biosciences) on the
BD Canto II flow cytometer according to manufactures instructions.
4.7. Pluripotency assay
Cell lines were assessed for differentiation potential using embryoid
bodies (EBs) and germ layer gene expression assessed using quantita-
tive PCR. Media was removed and the cells were washed with PBS.TrypLE™ was added for 3 min. DMEM containing 20% FCS was added
to quench the TrypLE. The cells were centrifuged at 300g for 3 min
and then resuspended in Apel™media (Stem Cell Technologies) con-
taining 10 μM Rock inhibitor at 30,000 cells per ml. 100 μl was then
added to each well of a U-bottom 96 well plate and centrifuged at
300g for 3 min. The plates were place in an incubator at 37 °C, 5% CO2.
EBs formed overnight and samples were collected at days 7 and 14.
RNA was extracted using Maxwell RSC machine and kit, according to
manufactures instructions (Promega). EB-derived cDNA was produced
using a High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems) according to manufacturer's instructions and analysed
with gene-specific probes (Applied Biosystems) by standard methods
and run on Quantstudio thermocycler (Thermofisher). For assessment
of cell line pluripotency each differentiated sample was compared
against its undifferentiated counterpart as a normalised control using
the DDCt method, to give relative quantitation (RQ) values using
GAPDH and ACTB as reference genes. Each batch of cells used to create
EBs were tested using specific antibodies to SSEA-1, SSEA-3, SSEA-4
and TRA1–60 (R&D Systems) on the BD Accuri flow cytometer accord-
ing to manufacturers' instructions.
4.8. Validation of hiPSC phenotype by high content image analysis
hiPSCs were seeded at a density of 1000–4000 cells/well on 96-well
μClear® cell culture plates (Greiner Bio One) pre-coated with Matrigel.
Adherent cellswerewashedwith PBS andfixed in 4%paraformaldehyde
in PBS for 20 min, then washed three times with PBS. Cells were then
permeabilized with 0.1% Triton X-100 for 10 min at room temperature
and washed 3 times with PBS. Cells were then blocked with serum
(3–5%) from the antibody producing host species in PBS for 30 min. In-
cubation with the respective primary antibodies in blocking solution
was performed overnight at 4 °C (Oct-3/4, sc-8629 (goat), Santa Cruz
Biotechnology Inc., 1:500; Sox2, sc-17320 (Y-17) (goat), Santa Cruz Bio-
technology Inc., 1:100; Lin28, 11724-1-AP (rabbit), Proteintech, 1:300;
Nanog, ab109250 (rabbit), abcam, 1:500). On the following day the
cells are washed 3 times with PBS. Alexa Fluor 488 (optimal for Opera
High Content Imaging System laser configuration) secondary antibodies
were diluted 1:500 in blocking solution and incubated with the cells for
4 h at room temperature in the dark. Cells were then washed 3 times
with PBS. Nuclear counterstaining was carried out with 2 μM Hoechst
33258 (Invitrogen). Cells were analysed on an Opera High Content Im-
aging System in combination with the Columbus Image Data Storage
and Analysis System (PerkinElmer). Laser power and exposure times
were adjusted to linear detection range to avoid detector saturation. Au-
tomated imaging was performed using 20× objectives and a sub layout
with 45 image fields per well (covering representative and defined
parts of the wells), resulting in image acquisition rates of approx. 1500
cells per well. For image analysis readily useable building blocks imple-
mented in the Columbus software (software version 2.6, PerkinElmer)
were applied. The image analysis algorithm sequence was generated
with Columbus building blocks (“nuclei detection”, “number of objects”
(nucleus and cytoplasm), “mean intensity nucleus”, “mean intensity cy-
toplasm”, “mean intensity cell”, “number of analysed fields”).
4.9. Database mining
The hPSCreg database includes data from EBiSC hiPSC – lines as well
as non-EBiSC lines. Lines can be registered freely, but public release of
lines requires a validation process. Validation is based on the provision
of mandatory data, including compliancewith standard ethical require-
ments, data providing sufficient evidence of pluripotency and others
related to derivation, cultivation, donor characteristics and data access
policy (https://hPSCreg.eu/docs/downloads/QuickStartGuideCellLine
Registration.pdf). We analysed two different categories of hiPSC –
lines in the hPSCreg database: (a) hiPSC lines that are registered and
validated (released) (n = 283 and (b) the Hot Start-lines (n = 27),
114 P.A. De Sousa et al. / Stem Cell Research 20 (2017) 105–114representing a subcategory of (a). Cell line specific hPSCreg-data of each
category was pre-processed and normalised with Java. The charts in
(Fig. 3) were generated in Microsoft Excel. Human embryonic stem
cell lines (hESC), which are also registered in hPSCreg, were not includ-
ed in the analysis.
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